

**Date:** 27<sup>th</sup> June, 2023

To,  
BSE Limited  
Phiroze Jeejeebhoy Tower,  
Dalal Street,  
Mumbai – 400001.

Dear Sir / Madam,

**Sub: Intimation of Trading Approval received for Rights Issue of Fully Paid-up Equity shares by Earum Pharmaceuticals Limited (“the Company”) under Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015.**  
**Ref: Security Id: EARUM / Code: 542724**

With reference to application made by the Company dated 25<sup>th</sup> January, 2023 regarding the proposed Rights Issue of Fully Paid-up Equity shares by the Company. We would like to inform you that the Company has received the Trading Approval from BSE Limited for the Rights Issue of Fully Paid-up Equity shares.

The approval letter received from the Stock Exchange i.e. BSE Limited is enclosed herewith.

Kindly take the same on record.

Thanking You.

**For, Earum Pharmaceuticals Limited**

**Bhumishth Patel**  
**Director**  
**DIN: 02516641**

**LOD / RIGHTS / SV / 262/ 2023-2024**

**" E - Letter "**

**Tuesday, June 27, 2023**

The Company Secretary  
**Earum Pharmaceuticals Limited**  
G1, Ground Floor, V R Complex,  
Near Sanathal Cross Road, SP Ring Road, Sanathal,  
Ahmedabad, Gujarat, 382210

Dear Sir / Madam,

**Re: Trading of 185432518 Equity Shares of Rs. 2/- issued at par on rights basis bearing distinctive Nos 61679101 to 247111618.**

We acknowledge with thanks the receipt of your application and subsequent submissions and have pleasure in advising that effective from **Wednesday, June 28, 2023** the above-mentioned securities are listed on the Exchange.

Please refer our Notice No. **20230627- 3** dated **June 27, 2023** available on our website issued in this behalf to the Trading Members of the Exchange, for your information, the contents of which may please be checked and confirmed to the Exchange.

Yours faithfully,

**SD/-**  
**Sabah Vaze**  
**Senior Manager**